Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tyra Biosciences, Inc. (TYRA : NSDQ)

• Company Description    Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $12.52 Daily Weekly Monthly 20 Day Moving Average: 233,604 shares Shares Outstanding: 53.30 (millions) Market Capitalization: $667.28 (millions) Beta: 1.10 52 Week High: $29.60 52 Week Low: $6.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.01% 14.95% 12 Week 31.79% 19.71% Year To Date -9.93% -19.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2656 STATE STREET - CARLSBAD,CA 92008 USA ph: 619-728-4760 fax: - aconrad@tyra.bio http://www.tyra.bio

• General Corporate Information    Officers Todd Harris - Chief Executive Officer and President Alan Fuhrman - Chief Financial Officer Adele M. Gulfo - Director Gilla Kaplan - Director Melissa McCracken - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90240B106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 53.30 Most Recent Split Date: (:1) Beta: 1.10 Market Capitalization: $667.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -46.88% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -31.22 03/31/25 - -26.90 12/31/24 - -22.98 ROA 06/30/25 - -29.49 03/31/25 - -25.54 12/31/24 - -21.94 Current Ratio 06/30/25 - 21.94 03/31/25 - 22.78 12/31/24 - 23.81 Quick Ratio 06/30/25 - 21.94 03/31/25 - 22.78 12/31/24 - 23.81 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 5.69 03/31/25 - 6.09 12/31/24 - 6.78 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©